BridgeBio Pharma, Inc.BBIONASDAQ

52-Week Range28-85

28.32Current 68.8384.94

Want to monitor BBIO?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

Gross Margin

Operating Margin

Revenue Growth

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform.

Professional, Scientific, and Technical Services

Research and Development in Biotechnology (except Nanobiotechnology)

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance

Alerts

News

Lumentum's OCS & CPO Strength Reflects Broader Demand: What's Ahead?

How Oklo's Nuclear Model Boosts Stability Amid Geopolitical Tensions

Carnival Gains From Strong Onboard Spending: A Yield Driver?

Can Carter's Retail Strength Offset Tariff Pressures in 2026?

Defense Stocks Are Surging and This ETF Lets You Collect Dividends From the Global Arms Race

Capital One Auto's ProtectID Wins 2026 “Fraud Prevention Innovation Award” for its Fraud Protection Tool

L'Oreal: Looking Interesting Again For Long-Term Investors (Upgrade)

FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile

3 Growth ETFs Down This Month and One of Them Is a Buy

Inflation worries tank gold, silver markets

Petrus Resources Ltd. (PRQ:CA) Q4 2025 Earnings Call Transcript

Micron benefits from memory demand

Micron's Insane Growth Doesn't Change Our Bearish Thesis

Reasons to Retain Avanos Medical Stock in Your Portfolio for Now

Red Cat Emerges In A High-Growth Market, Time To Ramp Up Production

If you invested $1,000 in Chevron stock at the start of 2026, here's your return now

Stifel Financial: A Wealth Manager's Stock for Wealth Investors

Meta to cut back on third-party vendors in favor of AI for content enforcement

Bronstein, Gewirtz & Grossman LLC Urges Camping World Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges PomDoctor, Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

About